Enhua Pharmaceutical: Wholly-owned subsidiary obtains exclusive commercial rights for three antipsychotic drugs in mainland China.

Enhua Pharmaceutical announced that its wholly-owned subsidiary Enhua Hexin signed an exclusive commercial cooperation agreement with Luye Pharma and Luye Jiaao, obtaining the exclusive commercialization rights in mainland China for three long-acting injectable antipsychotic drugs: Risperidone Microspheres for Injection, Paliperidone Palmitate Injection, and Paliperidone Palmitate Extended-release Injectable Suspension. The cooperation period is until December 31, 2035. Enhua Hexin will make a one-time payment of $20 million as authorization fee and achieve no less than 2.7 billion yuan in sales from 2026 to 2035. If the committed sales target is met, there will be a priority negotiation right within 2 months after the expiration of the agreement. This transaction does not constitute a related-party transaction or a major asset restructuring.